74630-84-5

Upstream product

• 599-67-7 1,1-diphenylethanol 

Downstream Products

• 258532-38-6 methyl (4-(2-(1,1-diphenylethylthio)ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 863911-77-7 2-[3-[2-(1,1-diphenylethylsulfonyl)ethyl]-2-hydroxymethylbenzofuran-7-yloxy]acetic acid methyl ester 
• 863911-41-5 {3-[2-(1,1-diphenyl-ethylsulfanyl)-ethyl]-2-hydroxymethyl-benzofuran-7-yloxy}-acetic acid 
• 863911-73-3 [3-[2-(1,1-diphenylethylsulfanyl)ethyl]-2-hydroxymethylbenzofuran-7-yloxy]acetic acid methyl ester 
• 258533-11-8 1-(1,1-diphenylethylthioacetyl)-5-hydroxy-1-chloroacetyl-1,2,3,4-tetrahydroquinoline 
• 258532-43-3 methyl (1-(2-(1,1-diphenylethylthio)ethyl)-2,3,4,5-tetrahydro-1H-benzazepin-6-yloxy)acetate 
• 881829-87-4 {1-[2-(1,1-diphenylethylsulfanyl)ethyl]-2,3-dihydro-1H-indol-4-yloxy}acetic acid methyl ester 
• 258532-29-5 methyl (4-(2-(1,1-diphenylethylthio)ethyl)-3,4-dihydro-2H-1,4-benzoxazin-8-yloxy)acetate 
• 863911-69-7 [3-[2-(1,1-diphenylethylsulfanyl)ethyl]-2-(tetrahydropyran-2-yloxymethyl)benzofuran-7-yloxy]acetic acid methyl ester 
• 863911-81-3 {2-(3-acetoxypropyl)-3-[2-(1,1-diphenylethylsulfanyl)ethyl]benzofuran-7-yloxy}acetic acid methyl ester 
• 863911-78-8 {2-(2-acetoxyethyl)-3-[2-(1,1-diphenylethylsulfanyl)ethyl]benzofuran-7-yloxy}acetic acid methyl ester 
• 863911-59-5 {3-[2-(1,1-diphenylethylsulfanyl)ethyl]benzofuran-7-yloxy}acetic acid methyl ester 

Relevant academic research and scientific papers

Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: Synthesis, structure-activity relationship, and evaluation of benzofuran derivatives

Prostacyclin (PGI2) is an unstable, powerful endogenous inhibitor of platelet aggregation, and thromboxane A2 (TXA 2) is an unstable endogenous arachidonic acid metabolite that plays a pivotal role in platelet aggregation and vasoconstriction. The balance between TXA2 and PGI2 greatly affects maintenance of the homeostasis of the circulatory system. A novel series of benzofuran-7- yloxyacetic acid derivatives was discovered as potent dual-acting agents to block the thromboxane A2 receptor and to activate the prostacyclin receptor. Synthesis, structure-activity relationship, and in vitro and ex vivo pharmacology of this series of compounds are described. The most potent in the series was {3-[2-(1,1-diphenylethylsulfanyl)ethyl]-2-hydroxymethylbenzofuran-7- yloxy}acetic acid diethanolamine salt (7) with Ki of 4.5 nM for thromboxane receptor antagonism and Ki of 530 nM for prostacyclin receptor agonism. Remarkably, compound 7 is a promising candidate for novel treatment as an antithrombotic agent with other cardiovascular actions to avoid hypotensive side effects.

A Novel Transformation of Alcohols to Thiols

Treatment of alcohols with 2,4-bis(p-methoxyphenyl)-1,3-dithiaphosphetane-2,4-disulphide (Lawesson reagent) gave the corresponding thiols.